Up until recently, measles vaccination has been so effective that there’s been little medical or financial incentive to develop treatments for the disease.

But as measles cases hit a 35-year high and vaccination rates continue to decline in the US, a handful of biotech companies and academic groups have started working on measles treatments for those infected with the virus as well as vulnerable individuals needing short-term protection. It will likely be years, however, before these countermeasures are available, and it’s even more uncertain if those who refuse vaccines would take such treatments.

Fueled by large outbreaks in South Carolina and Utah, the US had already surpassed last year’s 2,289 measles cases, and it’s only July. For comparison, there were just 285 cases in all of 2024.

Read full article

Comments

© Jan Sonnenmair/Getty Images

As the US sees its highest number of measles cases in decades and vaccination rates fall, researchers are developing drugs to help those who contract the virus or who are particularly vulnerable.

Outside experts—some with a vested interest in peptides—recommended adding a number of the amino acids to the FDA’s bulks list, including the “Wolverine stack” touted by Joe Rogan and other influencers.

The cyclospora diarrhea outbreak isn’t an isolated incident. It’s part of a pattern of leafy greens wreaking digestive havoc.

“Based on simple math, these outbreak responses—which require rapid, timely responses—are going to be greatly diminished,” the former CDC lab director tells WIRED.

On today’s Uncanny Valley, we unpack OpenAI’s ongoing drama, both legal and reputational, and whether these developments could further hurt the company—particularly in its fight against Anthropic.

Cyclosporiasis isn’t the only thing spreading across the US. So is anxiety about getting hit with it.

Official case counts likely capture only a fraction of US cyclosporiasis infections, and the outbreak is likely to get worse before it gets better.